Eagle Pharmaceuticals Says Granted Unique J-Code And Pass-Through Status For BARHEMSYS From CMS
Portfolio Pulse from Benzinga Newsdesk
Eagle Pharmaceuticals has been granted a unique J-Code and pass-through status for BARHEMSYS by the Centers for Medicare & Medicaid Services (CMS).
October 23, 2023 | 10:59 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eagle Pharmaceuticals' BARHEMSYS has been granted a unique J-Code and pass-through status by CMS, which could potentially increase its market accessibility.
The granting of a unique J-Code and pass-through status by CMS for Eagle Pharmaceuticals' BARHEMSYS could potentially increase its market accessibility and usage, which could lead to increased revenues for the company. This is likely to have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100